Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 20Colorectal Neoplasms 17Neoplasm Metastasis 17Lymphoma, Non-Hodgkin 15Ovarian Neoplasms 15Carcinoma, Renal Cell 14Leukemia 14Leukemia, Lymphocytic, Chronic, B-Cell 14Melanoma 14Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lung Neoplasms 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 10Hematologic Neoplasms 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Adenocarcinoma 9Glioma 9Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 9Prostatic Neoplasms 9Stomach Neoplasms 9

Interventions

trametinib 1ripretinib 1dabrafenib 1avapritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Gastrointestinal Stromal Tumors × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT03353753 2022-11-21

INVICTUS

Deciphera Pharmaceuticals, LLC

Phase 3 Completed
129 enrolled 19 charts 1 FDA
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02508532 2022-06-21

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Blueprint Medicines Corporation

Phase 1 Completed
250 enrolled 36 charts 1 FDA
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡